Abstract
The authors have used the thymidine kinase/ganciclovir system to block glioblastoma multiforme neoplastic cells in vivo, both in experimental animals and in two patients in which the more conventional therapies had been unsuccessful. In the Wistar rat it was found that the curability potential of the system is correlated with tumoral volume. Tumours smaller than 20 mm3 can be cured with defective retrovirus that do not carry the Herpes simplex thymidine kinase (Hsvtk) gene. While tumours smaller than 150 mm3 can regress totally by the kinase/ganciclovir system, those above that size cannot be cured by this treatment. In humans the situation seems very similar in that the authors have been unable either to reduce the tumour size of recurrent patients with tumour volumes larger than 100 cm3 applying the standard thymidine kinase/ganciclovir gene therapy or to prolong their survival time more than 8 months [7]. When a combination of size reduction by neurosurgery and gene therapy was used the survival time increased considerably. Two patients have been treated by partial surgery and repeated treatment with thymidine kinase/ganciclovir through an Ommaya reservoir connected to a catheter leading into the tumour cavity. The magnetic resonance imaging (MRI) of these patients show only a residual tumoral growth along side the tumoral bed. The procedure may be partially controlling the proliferation of cancerous cells, because, these two patients having recurrent glioblastoma, are alive 11 and 17 months after the beginning of the treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Culver KW, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550–1552.
Culver K et al (1994) Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with herpes simplex thymidine kinase gene/ganciclovir system (clinical protocol). Hum Gene Ther 5: 343–379
Danos O (1991) Construction of retroviral packaging cell lines. Methods Mol Biol 8: 17–27
Elshami AA et al (1996) Gap junctions play a role in the “bystander effect” of the herpes simplex virus thymidine kinase/ ganciclovir system in vitro. Gene Ther 3: 85–92
Freeman SM et al (1993) The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274–5283
Izquierdo M Cortés M, de Felipe P, Martín V, Diéz-Guerra J, Talavera A, Perez-Higueras A (1995) Long term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther 2: 66–69
Izquierdo M, Martín V, de Felipe P, Izquierdo JM, Pérez-Higueras A, Cortés ML, Paz JF, Isla A, Blázquez MG (1996) Human malignant brain tumor response to Herpes Simplex thimidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther 3: 491–495
Li Bi W, Parysek LM, Warnick R, Stambrook PJ (1993) In vitro evidence that metabolic cooperation is responsible for the bystander effect observed whith HSVtk retroviral gene therapy. Hum Gene Ther 4: 725–731
Miller AD, Miller DG, Garcia JV, Lynch CM (1993) Use of retroviral vectors for gene transfer and expression. Meth Enzymol 217: 581–599
Miller AD, Rosman GJ (1989) Improved retroviral vectors for gene transfer and expression. BioTechniques 7: 980–990
Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res 46: 5276–5281
Morgenstern J, Land H (1990) Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell Une. Nue Acid Res 18: 3587–3596
Peterson DL, Sheridan PJ, Brown WE (1994) Animal models for brain tumors: historical perspectives and future directions. J Neurosurg 80: 865–876
Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH (1993) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53: 83–88
Ram Z, Culver KW, Walbridge Frank JA, S., Blaese RM, Oldfield EH (1993) Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J Neurosurg 79: 400–407 \ai]16._Short MP, Choi BC, Lee JK, Malick A, Breakefield XO, Martuza RL (1990) Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res 27: 427–433
Takamiya Y, Short MP, Ezzeddine ZD, Moolten FL, Breakefield XO, Martuza RL (1992) Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res 33: 493–503
Wu JK et al (1994) Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 35: 1094–1102
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1997 Springer-Verlag Wien
About this paper
Cite this paper
Izquierdo, M. et al. (1997). Gene Therapy in Brain Tumours: Implications of the Size of Glioblastoma on its Curability. In: Ostertag, C.B., Thomas, D.G.T., Bosch, A., Linderoth, B., Broggi, G. (eds) Advances in Stereotactic and Functional Neurosurgery 12. Acta Neurochirurgica Supplements, vol 68. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6513-3_21
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6513-3_21
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-7341-1
Online ISBN: 978-3-7091-6513-3
eBook Packages: Springer Book Archive